Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 4Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 3Observational 2

Sponsor

Conditions

Lymphoma, Non-Hodgkin 130Lymphoma, Large B-Cell, Diffuse 101Lymphoma, Follicular 90Leukemia, Lymphocytic, Chronic, B-Cell 82Lymphoma 63Lymphoma, B-Cell 43Recurrence 31Lymphoma, Mantle-Cell 30Lymphoma, B-Cell, Marginal Zone 23Neoplasms 22Leukemia 10Hematologic Diseases 10Lymphatic Diseases 8Multiple Myeloma 7Immunoproliferative Disorders 6Hematologic Neoplasms 6Waldenstrom Macroglobulinemia 5Lymphoproliferative Disorders 5Leukemia, B-Cell 5Arthritis, Rheumatoid 5Hodgkin Disease 4Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Immune System Diseases 3Dendritic Cell Sarcoma, Interdigitating 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2

Interventions

Methotrexate 10Adalimumab 6tocilizumab 5Rituximab 5olokizumab 4tofacitinib 3Etanercept 3golimumab 2RC-18 2Abatacept 2veltuzumab 1upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1baricitinib 1andecaliximab 1Tumor Necrosis Factor Inhibitors 1TACI receptor-IgG Fc fragment fusion protein 1Sulfasalazine 1Pharmaceutical Preparations 1Leflunomide 1Interleukin 1 Receptor Antagonist Protein 1Infliximab 1ISIS104838 1Hydroxychloroquine 1Folic Acid 1Double-Blind Method 1Chloroquine 1CT-P13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Arthritis, Rheumatoid × Rituximab × Clear all
NCT06175338 2024-09-19

Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis

Mabscale, LLC

Phase 1 Active not recruiting
208 enrolled

Arthritis, Rheumatoid

NCT00503425 2017-08-15

A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.

Hoffmann-La Roche

Phase 3 Completed
215 enrolled 9 charts

Arthritis, Rheumatoid

NCT00468546 2016-10-25

A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy

Hoffmann-La Roche

Phase 3 Completed
520 enrolled 17 charts

Arthritis, Rheumatoid

NCT01613027 2016-10-24

An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis

Hoffmann-La Roche

Completed
135 enrolled 21 charts

Arthritis, Rheumatoid

NCT01641952 2016-08-17

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent

Hoffmann-La Roche

Completed
505 enrolled 15 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡